Skip to main content

Table 1 Influenza virus vaccines for the United States of America 2013–2014 season a

From: Properties and prospects of adjuvants in influenza vaccination - messy precipitates or blessed opportunities?

Seasonal influenza vaccines

Type/abbrev.

# Antigens

Route of administration

Manufacturer

Age range

Adjuvant

Afluria

Inactivated/IIV3b

Trivalent

Intramuscular

CSL Limited

5 ≥

None

FluLaval

Inactivated/IIV3b

Trivalent

Intramuscular

GlaxoSmithKline

18 ≥

None

Fluarix

Inactivated/IIV3b

Trivalent

Intramuscular

GlaxoSmithKline

3 ≥

None

Inactivated/IIV4b

Quadrivalent

Intramuscular

None

Flublok

Recombinant/RIV3c

Trivalent

Intramuscular

Protein Sciences

18-49

None

Flucelvax

Cell Culture/ccIIV3b

Trivalent

Intramuscular

Novartis

18 ≥

None

FluMist

Live Attenuated/LAIV4d

Quadrivalent

Intranasal

Medimmune

2-49

None

Fluvirin

Inactivated

Trivalent

Intramuscular

Novartis

4 ≥

None

Fluzone

Inactivated/IIV3b

Trivalent

Intramuscular

Sanofi Pasteur

6 mo ≥e

None

 

Inactivated/IIV4b

Quadrivalent

Intramuscular

None

  1. aU.S. Food and Drug Administration recommends that the trivalent-formulation influenza vaccines for the U.S. 2013–2014 influenza season contain the following: (1) A/California/7/2009 (H1N1)-like virus, (2) (H3N2) virus antigenically like the cell-propagated prototype virus A/Victoria/361/2011, and (3) B/Massachusetts/2/2012-like virus. For the quadrivalent-formulation influenza vaccines for the U.S. 2013–2014 influenza season contain the above three strains and the following additional B strain: (4) B/Brisbane/60/2008-like virus. bIIV refers to inactivated vaccines (egg and cell-culture based). Includes trivalent (IIV3) and quadrivalent (IIV4). cRIV refers to recombinant HA influenza vaccine. Trivalent (RIV3). dLAIV refers to Live Attenuated Influenza Vaccine. Quadrivalent (LAIV4). eDose dependent. Informations were found on web sites: http://www.emergency.cdc.gov/coca/ppt/2013/08_13_13_Immunizations.pdf, http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/post-marketactivities/lotreleases/ucm343828.htm (accessed on 4 September 2013).